Trial reportClinical pharmacology and therapeutics2008
Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.
Trial report in Clinical pharmacology and therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Cytochrome P450 2A6 deletion polymorphism and risk of lung cancer: a meta-analysis.Molecular biology reports · 2013Pooled it
- Systematic review of the relationship between the 3-hydroxycotinine/cotinine ratio and cigarette dependence.Psychopharmacology · 2011Pooled it
- Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers.Clinical pharmacology and therapeutics · 2009Trial
- Association Between Blood Benzene Levels and Periodontal Disease in a Nationally Representative Adult U.S. Population.International journal of environmental research and public health · 2025Article
- The Influence of Cytochrome P450 Polymorphisms on Pharmacokinetic Profiles and Treatment Outcomes Among Malaria Patients in Sub-Saharan Africa: A Systematic Review.Pharmacogenomics and personalized medicine · 2023Review
- Quantitative Proteomics in Translational Absorption, Distribution, Metabolism, and Excretion and Precision Medicine.Pharmacological reviews · 2022Review
- Tobacco and nicotine use.Nature reviews. Disease primers · 2022Review
- Nicotine metabolism and its association with CYP2A6 genotype among Indigenous people in Alaska who smoke.Clinical and translational science · 2021Article
- Pharmacogenomics of Nicotine Metabolism: Novel CYP2A6 and CYP2B6 Genetic Variation Patterns in Alaska Native and American Indian Populations.Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco · 2020Article
- The Novel CYP2A6 Inhibitor, DLCI-1, Decreases Nicotine Self-Administration in Mice.The Journal of pharmacology and experimental therapeutics · 2020Article
- Genetic polymorphisms of the drug-metabolizing enzyme cytochrome P450 2A6 in a Tibetan Chinese population.International journal of clinical and experimental pathology · 2018Article
- Variation in CYP2A6 Activity and Personalized Medicine.Journal of personalized medicine · 2017Review
- Interaction between cytochrome P450 2A6 and Catechol-O-Methyltransferase genes and their association with smoking risk in young men.Behavioral and brain functions : BBF · 2017Article
- Variation in CYP2A6 and nicotine metabolism among two American Indian tribal groups differing in smoking patterns and risk for tobacco-related cancer.Pharmacogenetics and genomics · 2017Article
- CYP2A6 genotyping methods and strategies using real-time and end point PCR platforms.Pharmacogenomics · 2016Article
- Preliminary investigation of the contribution of CYP2A6, CYP2B6, and UGT1A9 polymorphisms on artesunate-mefloquine treatment response in Burmese patients with Plasmodium falciparum malaria.The American journal of tropical medicine and hygiene · 2014Article
- High CYP2A6 enzyme activity as measured by a caffeine test and unique distribution of CYP2A6 variant alleles in Ethiopian population.Omics : a journal of integrative biology · 2014Article
- Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability.Neuropharmacology · 2014Review
- A compensatory effect upon splicing results in normal function of the CYP2A6*14 allele.Pharmacogenetics and genomics · 2013Article
- The Twin Research Registry at SRI International.Twin research and human genetics : the official journal of the International Society for Twin Studies · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
Cytochrome P450 2A6 (CYP2A6) is the human enzyme responsible for the majority of nicotine's metabolism. CYP2A6 genetic variants contribute to the interindividual and interethnic variation in nicotine metabolism. We examined the association between the CYP2A6*1B variant and nicotine's in vivo metabolism. Intravenous infusions of deuterium-labeled nicotine were administered to 292 volunteers, 163 of whom were White and did not have common CYP2A6 variants, other than CYP2A6*1B. We discovered three novel CYP2A6*1B variants in the 3'-flanking region of the gene that can confound genotyping assays. We found significant differences between CYP2A6*1A/*1A, CYP2A6*1A/*1B, and CYP2A6*1B/*1B groups in total nicotine clearance (17.2+/-5.2, 19.0+/-6.4, and 20.4+/-5.9, P<0.02), non-renal nicotine clearance (16.4+/-5.0, 18.5+/-6.2, and 19.8+/-5.7, P<0.01), and the plasma trans-3'-hydroxycotinine/cotinine ratio (0.26+/-0.1, 0.26+/-0.1, and 0.34+/-0.1, P<0.001). There were also differences in total nicotine (29.4+/-12.9, 25.8+/-0.12.9, and 22.4+/-12.4, P<0.01), cotinine (29.2+/-8.1, 32.2+/-9.1, and 33.0+/-6.6, P<0.01) and trans-3'-hydroxycotinine (32.4+/-9.1, 34.2+/-12.3, and 41.3+/-11.3, P<0.001) excreted in the urine. We report evidence that CYP2A6*1B genotype is associated with faster nicotine clearance in vivo, which will be important to future CYP2A6 genotype association studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.